Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors.

ABSTRACT:

Background

EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the clinical and therapeutic significance of uncommon EGFR mutations is uncertain.

Methods

This is a single-center retrospective study of patients with EGFR-mutant lung cancer (2009-2017). Molecular analyses of EGFR exons 18-21 were performed. Only patients with uncommon mutations were included (p.Glu709X, p.Gly719X, p.Ala767_Val769 dup, p.Ser768Ile, and p.Leu861Gln).

Results

Among 6,747 tumor samples, 95 out 820 patients (11.6%) harbored 113 uncommon EGFR mutations. There were 50 metastatic NSCLC patients for whom the median OS was 18.0 months (95% CI: 15, 32). I

SUBMITTER: Brindel A 

PROVIDER: S-EPMC7578497 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature